ClinicalTrials.gg
CompletedNCT00813618Pediatric GvHDUpdated Dec 23, 2008

Study of MEDI 507 in the Treatment of Pediatric Patients

A Phase 1 interventional study of MEDI-507 and MEDI-507 in Graft Versus Host Disease, sponsored by MedImmune LLC. Completed at 6 sites in United States. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2008-12-23.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.

Enrollment
290th of 389
10 · median 30
Started
1999
with 14 others
Phase 1
90 of 454
14 open now
Registered
183rd of 454
by date

Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 290th largest by enrollment of the 389 interventional ones that give a count, is one of 15 that started in 1999, is one of 90 in phase 1, and was the 183rd registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Graft vs Host Disease with a site in United States, or all of them as a file.
02

Study summary

To assess the safety of escalating dose levels of MEDI-507 in pediatric stem cell and bone marrow allograft recipients who have at least Grade II GvHD.

Read the detailed description

This is a Phase I, open-label dose escalation trial of MEDI-507 in pediatric SCT and BMT recipients with at least Grade II acute GvHD. All patients will receive steroid therapy and MEDI-507 for treatment of GvHD

03

Conditions studied

  • Graft Versus Host Disease

Browse trials for

Keywords

  • Acute GvHD of at least Grade II severity
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • BMT or SCT recipients
  • Acute GvHD of at least Grade II severity
  • Age 2 to 17 years
  • Evidence of engraftment (ANC over 500 cells/mm3 on two consecutive days within seven days before study entry)
  • Receipt of GvHD prophylaxis regimen including methotrexate, tacrolimus or cyclosporine
  • Receipt of at least 2 mg/kg of methylprednisolone (or equivalent ) between eight and 24 hours prior to the first MEDI-507 dose for GvHD treatment
  • Both males and females are eligible, but sexually active females at risk of pregnancy of must agree to use an effective method of avoiding pregnancy (which includes oral or implanted , IUD, female condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual partner) beginning 30 days before the first study infusion and continuing through 60 days after the final study infusion.

Exclusion criteria

Exclusion Criteria:

  • Treatment of acute GvHD with methylprednisolone (or equivalent ) at a total dose exceeding 14 mg/kg (or equivalent) over a seven day period (for example, 2 mg/kg/day for seven days)
  • Previous receipt of MEDI 507
  • Previous treatment with any anti-T cell monoclonal antibodies, such as OKT3, daclizumab (Zenapax), or basiliximab (Simulect)
  • Treatment with anti-thymocyte globulin (ATG, ATGAM or others) within 14 days
  • More than one allogeneic bone marrow or hematopoietic stem cell allograft
  • Use of other agents within 30 days (this does not include the use of licensed agents for indications not listed in the package insert) or current participation in a research protocol in which an investigational agent was administered
  • Any of the following clinical settings or diagnoses:
  • documented or presumed significant active infection
  • pregnancy or nursing mother
  • evidence of infection with -1, or C virus
  • hemodialysis or chronic peritoneal dialysis
  • use of a ventilator
  • chronic GvHD
  • active veno-occlusive disease of the liver
  • moribund patient
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    1

    MEDI-507

    Drug: MEDI-507

  • Experimental
    2

    MEDI-507

    Drug: MEDI-507

  • Experimental
    3

    MEDI-507

    Drug: MEDI-507

Interventions

  • 0.012 mg/kg given intravenously on Study Days 0, 3, 6 and 9

  • 0.04 mg/kg given intravenously on Study Days 0, 3, 6 and 9

  • 0.12 mg/kg given intravenously on Study Days 0, 3, 6 and 9

06

What researchers measure

Primary outcomes

  1. Safety assessment of escalating dose levels of MEDI-507 in pediatric stell scell (SCT) and bone marrow (BMT) allograft recipients who have at least Grade II Graft-versus-Host Disease (GvHD).

    Time frame: Through Study Day 44

Secondary outcomes

  1. Evaluate the serum concentrations and pharmacokinetics (PK) of MEDI 507 and pharmacodynamic effects of MEDI-507 on the absolute lymphocyte count and dynamics of lymphocyte phenotypes.

    Time frame: Through Study Day 364

07

Study locations

6 sites
  • Children's Hospital
    Birmingham, Alabama 35233, United States
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • Children's Memorial Hospital
    Chicago, Illinois 606014, United States
  • Univ. of Michigan Medical Center
    Ann Arbor, Michigan 48109, United States
  • Hackensack U. Medical Center
    Hackensack, New Jersey 07601, United States
  • The Children's Hosp. of Phila., Abramson Ped. Research Center
    Philadelphia, Pennsylvania 19104, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 1999, a primary completion of Jun 2004 and a completion of Aug 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2008
First posted
Dec 23, 2008
Start
Sep 1999
Primary completionActual
Jun 2004
CompletionActual
Aug 2004
Last update
Dec 23, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00813618
Lead sponsor
MedImmune LLC
First posted
Dec 23, 2008
Start date
Sep 1999
Primary completion
Jun 2004
Completion
Aug 2004
Last update
Dec 23, 2008

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Siplizumab

Start the discussion